All PlansCoverageHigh impact
Recall: Semglee
UPMC Health Plan·Endocrinology, Internal Medicine, Family Medicine +1 more·Pharmacy
Effective date
Feb 1, 2022
We identified it
Aug 7, 2026
Summary
Mylan Pharmaceuticals (Viatris) has issued a recall for specific batches of Semglee® (insulin glargine injection) 100 units/ml in 3mL prefilled pens. The billing team must identify patients who received affected batches and coordinate with providers and pharmacy to ensure patient safety, document the recall in patient records, and manage any related billing adjustments or replacement therapy claims.
Action Required
Immediately: Billing and clinical teams must (1) identify all patients billed for Semglee (J7309) who may have received recalled batches; (2) cross-reference patient records with recall batch numbers from the full recall text at https://www.upmchealthplan.com/providers/medical/announcements-updates/announcements/2022-announcements/02-01-recall-semglee; (3) notify affected patients and providers; (4) coordinate with pharmacy for replacement pens; (5) document the recall event in billing records and patient charts; (6) process replacement therapy claims appropriately; (7) monitor for any claim denials related to the recall and work with UPMCHealthPlan for resolution. Failure to identify and manage recalled inventory could result in patient safety incidents and potential billing complications.